Pioneering solutions, saving lives
Research is critical to combatting brain disease and improving the lives of those impacted, today and in the future.
Conducted by The Royal Melbourne Hospital’s Departments of Neurology and Neurosurgery, the active research programs and clinical trials supported by the Foundation cover an extensive breadth of neurological conditions.
Patients wishing to participate are encouraged to view the relevant trial and contact the trial co-ordinator for more information.
| Brain Tumour / Neurosurgery: | NsurgClerk@mh.org.au |
| Dementia: | DementiaTrials@mh.org.au |
| Epilepsy: | EpilepsyCoordinator@mh.org.au |
| Huntington’s Disease: | RMHHuntingtonDiseaseStudies@mh.org.au |
| Movement Disorders: | PDNurse@mh.org.au |
| Multiple Sclerosis: | MSClinic@mh.org.au |
| Neurophysiology: | RMH-ClinicalNeurophysiology@mh.org.au |
| Stroke: | RMH-StrokeResearchTeam@mh.org.au |
| General: | Neuro.Foundation@mh.org.au |
A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study of IMVT-1402 Treatment in Adult Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
exPDite-2: A Phase 3 Study to Assess the Efficacy and Safety of Midbrain Dopaminergic Neuronal Cell Therapy (Bemdaneprocel) for Participants With Parkinson's Disease
A Phase 2, Randomized, Double-blind, Four-Arm, Placebo-Controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of three doses of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Spasticity in Participants with Multiple Sclerosis (BALANCE-MSS-1)
Treatment Of Stroke reCurrence in Cerebral Amyloid Angiopathy (CAA) with TraneXamic Acid (TOSCCAA-TXA)
A phase III randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of treatment with corticoSTeroids at onset, And Rituximab during a relapse, of Myelin Oligodendrocyte Glycoprotein antibody-associated disease